Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 3, 2003, Pages 155-167

  Sandström, Eric ^a   Uhnoo, Ingrid ^b,c   Ahlqvist Rastad, Jane ^c   Bratt, Göran ^a   Berglund, Torsten ^d   Gisslén, Magnus ^e   Lindbäck, Stefan ^f   Morfeldt, Linda ^c,f   Ståhle, Lars ^f   Sönnerborg, Anders ^f   Albert, J ^f   Beermann, B ^c   Bergbrant, I M ^g   Bohlin Wiechel, A B ^f   Brandt, C ^c   Flamholc, L ^h   Gaines, H ^d   Hamberg, A K ^c   Jonsson, B ^c   Koppel, K ^a   Lidman, K ^f   Lindback S ^f   Lindgren, S ^f   Magnusson, S ^j   Moberg, L ^f   Nilsson, A ^a   Nilsson Schonesson L ^a   Nilsson, P ^c   Pehrsson, P O ^f   Reinnel, H ⁱ   Schvarcz, R ^f   Svennerholm, B ^g   Wahren, B ^d   Wejstal R ^e   Akerlund B ^f   more..

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ Norwegian Medicines Contr Authority   (Norway)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DATA ANALYSIS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; GLUCOSE INTOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTERNET; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL RESEARCH; METABOLIC DISORDER; MUSCLE DISEASE; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; PUBLICATION; RASH; RHABDOMYOLYSIS; STANDARD; SWEDEN; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HUMANS; MALE; PRACTICE GUIDELINES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SWEDEN; TREATMENT OUTCOME;

EID: 0038025414     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310006395     Document Type: Article

References (26)

1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288: 222-35.
2. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://www. hivatis.org/ (4 February 2002).
3. Robbins G, Shafer R, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, et al., for the ACTG Team. Antiretroviral strategies in treatment naive HIV + subjects. (ACTG 384) XIV International AIDS Conference, 2002. LbOr20A and B.
4. Krolewiecki AJ, Bouzas MB, Cahn P, Cassetti I, Zala C, Gun A, et al. Treatment discontinuation in patients who started antiretroviral therapy following the 1996 IAS-USA recommendations. A prospective randomized trial. XIV International AIDS Conference, 2002. ThOrB1440.
5. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl 2): S171-6.
6. Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 1999; 13: 1677-85.
7. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14.
8. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186: 189-97.
9. van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6: 201-29.
10. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
11. Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, et al. Final analysis of the Trilege induction-maintenance trial: results at 18 months. AIDS 2002; 16: 561-8.
12. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-26.
13. Lindback S, Brostrom C, Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 × 106/1, AIDS, and death from AIDS? Br Med J 1994; 309: 1535-7.
14. Hoen B, Dumon B, Harzic M, Venet A, Dubeaux B, Lescoux C, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J Infect Dis 1999; 180: 1342-6.
15. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 2001; 50(RR-11): 1-52.
16. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54.
17. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
18. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179: 1375-81.
19. Lederman MM. Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS 2001; 15 (Suppl 2): S11-5.
20. Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD, HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617-26.
21. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195.
22. Birk M, Svedhem V, Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15: 1359-68.
23. Acostas EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18: 825-34.
24. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-8.
25. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-18.
26. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chrisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.